Lipigon Pharmaceuticals AB (publ) (STO:LPGO)
0.0110
0.00 (0.00%)
Feb 11, 2026, 1:32 PM CET
STO:LPGO Revenue
Lipigon Pharmaceuticals AB had revenue of 1.32M SEK in the twelve months ending September 30, 2025, down -85.32% year-over-year. In the year 2024, Lipigon Pharmaceuticals AB had annual revenue of 10.29M, down -37.30%.
Revenue (ttm)
1.32M
Revenue Growth
-85.32%
P/S Ratio
5.06
Revenue / Employee
188.14K
Employees
7
Market Cap
6.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.29M | -6.12M | -37.30% |
| Dec 31, 2023 | 16.41M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 2.21M | -1.80M | -44.86% |
| Dec 31, 2020 | 4.01M | 2.27M | 130.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nanologica AB | 22.65M |
| Fluicell AB | 13.20M |
| AcouSort AB | 10.80M |
| NanoEcho AB | 3.43M |
| Aptahem AB | 2.47M |
| 2cureX AB | 1.98M |
| Stayble Therapeutics AB | -340.00K |
| LIDDS AB | -911.00K |